Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 12/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 1/20 | 0.35 |
| ▸ | DRD4 | P21917 | 2/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2220820 | 0.96 | HRH3 (0.52) | HRH3LMNAHTTKDM4EMAPK1 | |
| SCHEMBL2219249 | 0.86 | HRH3 (0.51) | HRH3LMNAHTTKDM4EMAPK1 | |
| SCHEMBL2217985 | 0.83 | HRH3 (0.53) | HRH3LMNAHTTKDM4EMAPK1 | |
| SCHEMBL2218809 | 0.83 | HRH3 (0.57) | HRH3LMNAHTTKDM4EMAPK1 | |
| SCHEMBL2218849 | 0.83 | HRH3 (0.54) | HRH3LMNAHTTKDM4EMAPK1 | |
| SCHEMBL2215718 | 0.80 | HRH3 (0.47) | HRH3LMNAHTTKDM4EMAPK1 | |
| SCHEMBL2215813 | 0.74 | HRH3 (0.49) | HRH3LMNAHTTKDM4EMAPK1 | |
| SCHEMBL2216475 | 0.73 | HRH3 (0.86) | HRH3LMNA | |
| SCHEMBL2215807 | 0.72 | HRH3 (0.54) | HRH3LMNAHTTKDM4EMAPK1 | |
| SCHEMBL2220952 | 0.69 | ALDH1A1 (0.55) | HRH3LMNAHTTKDM4EMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178062-A1 | INDOLE AND BENZOTHIOPHENE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178062-A1 | INDOLE AND BENZOTHIOPHENE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | HRH3, HRH4, HRH1 | HRH3 1/4885LMNA 4860/4885HTT 139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.